On the one hand, in patients with stage III and stage IV melanomas, the presence of BRAF mutation has been shown to be associated with a worse outcome compared to patients with BRAF wildtype melanomas (Hugdahl et al. 2016; Long et al. 2011; Ekedahl et al. 2013; Moreau et al. 2012). This evidence concerns the gene BRAF and melanoma.